Real-World Treatment Patterns and Survival in People With Metastatic Castration-Resistant Prostate Cancer Following Metastatic Hormone-Sensitive Disease Between 2020 and 2023 in the United States
Back-to-back ARPI use from mHSPC to mCRPC is common in current clinical practice and survival remains <3 years. Alternative mCRPC treatments, such as intensified combination regimens beyond androgen receptor targeting, require exploration to improve survival in mCRPC.
Authors
- Stephen J. Freedland (ORCID: https://orcid.org/0000-0002-8104-6419)
- Andreas Bernthaler
- Matthew J. Korn
- Amit D. Raval (ORCID: https://orcid.org/0000-0001-8265-8612)
- Niculae Constantinovici
- Guifang Chen
Institutions
- Cedars-Sinai Medical Center (US)
- Bayer (United States) (US)
- Bayer (Switzerland) (CH)
- Durham VA Medical Center (US)
- Bayer (Germany) (DE)
Publication Details
- Journal
- Clinical Genitourinary Cancer
- Published
- 2025-06-18
- DOI
- https://doi.org/10.1016/j.clgc.2025.102386
- Citations
- 2
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 3.04
Funders
- Bayer
- Bayer Corporation